Trials / Terminated
TerminatedNCT04478825
Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis
An Open Label, Proof of Mechanism Study to Explore the Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Bridge Biotherapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single-arm, proof of mechanism study to explore the efficacy and safety of rectally administered BBT-401-1S in subjects with ulcerative colitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BBT-401-1S | BBT-401-1S, 8 weeks, once a day |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2021-08-04
- Completion
- 2021-08-24
- First posted
- 2020-07-21
- Last updated
- 2021-10-01
Locations
2 sites across 1 country: New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04478825. Inclusion in this directory is not an endorsement.